Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECTRIMS 2022 | Reappraisal of the 2017 McDonald criteria for multiple sclerosis

Jaume Sastre-Garriga, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, discusses possible changes to the 2017 McDonald criteria used to aid the diagnosis of multiple sclerosis (MS). Potential modifications feature the inclusion of optic nerve lesions as a fifth element for dissemination in space; whether optical coherence tomography (OCT) angiography or MRI should be used is still under discussion. Increasing the specificity of the MRI findings by describing the location and shape of the lesions and the inclusion of the central vein sign (CVS) and paramagnetic rim lesions (PRL) are also possible additions to the criteria. Additionally, radiologically isolated syndrome should be included in the diagnostic criteria of MS. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


J Sastre-Garriga has received grants and personal fees from Genzyme, personal fees from Almirall, Biogen, Celgene, Merck, Bayer, Biopass, Bial, Novartis, Roche and Teva, and he is European co-Editor of Multiple Sclerosis Journal and Scientific Director of Revista de Neurologia.